Home
    Disclaimer
    Methylenedioxyphenmetrazine molecular structure

    Methylenedioxyphenmetrazine Stats & Data

    Mdpm 3-mdpm 3,4-mdpm
    NPS DataHub
    MW257.72
    FormulaC12H16ClNO3
    IUPAC2-(Benzo[d][1,3]dioxol-5-yl)-3-methylmorpholine hydrochloride
    SMILES[Cl-].CC1NCCOC1c1ccc2OCOc2c1.[H+]
    InChIKeyQONZUIUPTNMPHT-UHFFFAOYSA-N
    Phenylmorpholines
    Chemical Class Amphetamine
    Psychoactive Class Stimulant
    Half-Life Unknown (no human PK studies located as of Nov 7, 2025); functional duration typically 4–7 h by mouth per user reports.

    Effect Profile

    Curated
    Stimulant 5.4

    Strong anxiety/jitters and euphoria with mild stimulation and focus

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    9
    Focus / Productivity×2
    5
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (no human PK studies located as of Nov 7, 2025); functional duration typically 4–7 h by mouth per user reports.
    Addiction Potential
    Presumed moderate; similar to other amphetamine-like stimulants. Strong habit-forming potential cannot be excluded; avoid multi-day runs and frequent redosing. Evidence quality: indirect (stimulant class risk) + anecdotal.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~28d

    Model is heuristic for HR spacing guidance, not a pharmacometric estimate. Expect rapid tolerance with consecutive-day use and partial cross-tolerance with other stimulants. Data quality: anecdotal/theoretical.

    Cross-Tolerances

    Amphetamine-class stimulants
    50% ●○○
    Phenmetrazine analogues (e.g., 3-FPM)
    60% ●○○

    Harm Reduction

    drugs.wiki

    Identity and potency are uncertain in the unregulated market; MDPM has been explicitly marketed as an MDMA substitute on forums, so do not assume contents—use multi-reagent testing and, where available, lab drug checking to confirm identity before any bioassay. Avoid repeating the claim that MDPM is a typical MDMA synthesis impurity; available community evidence points instead to intentional sale as its own product, not a routine MDMA by-product. Onset can be slower than expected for a stimulant (especially orally), which encourages premature redosing—wait at least 90–120 minutes before considering more to avoid accidental overuse. Cardiovascular strain (tachycardia, increased blood pressure) is possible; people with uncontrolled hypertension, arrhythmia, or cardiovascular disease should avoid use. Stay cool, take rest breaks, and sip isotonic fluids (avoid both dehydration and overhydration). General stimulant HR supports these measures. Intranasal use can irritate/damage nasal mucosa; if snorting, finely powder, split lines, and use pre/post isotonic saline rinses; consider oral as a lower-harm ROA. Combining with MAOIs, tramadol, or DXM elevates serotonin-toxicity and seizure risks; avoid these combinations entirely. Use extra caution with SSRIs/SNRIs (possible blunting or unpredictable interactions). TripSit’s combo guidance and HR pages support avoiding serotonergic/stimulant risk stacks. Sleep disruption is common; plan ahead, avoid late redoses, and favor non-alcoholic comedown strategies (nutrition, hydration, sleep hygiene; consider OTC sleep aids like melatonin only if appropriate). Pharmacokinetic data in humans are lacking; any in vitro ‘half-life’ figures should not guide dosing. Treat half-life as unknown and dose conservatively, leaving long gaps between sessions. Some users report mild empathic warmth rather than classic MDMA-like entactogenesis; expectations should be set accordingly to reduce risky redosing in search of absent effects. If using regularly, schedule long breaks (weeks) to limit tolerance and dependence; stimulant binges increase risks of psychosis and compulsive redosing as seen with other stimulants.

    ← Back to Methylenedioxyphenmetrazine